<- Go home

Added to YB: 2024-10-28

Pitch date: 2024-09-30

VCYT [bullish]

Veracyte, Inc.

+26.6%

current return

Author Info

No bio for this author

Company Info

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.

Market Cap

$3.1B

Pitch Price

$33.84

Price Target

N/A

Dividend

N/A

EV/EBITDA

32.57

P/E

103.44

EV/Sales

5.62

Sector

Biotechnology

Category

growth

Show full summary:
Artisan Small Cap Fund Portfolio Holding: Veracyte, Inc.

VCYT: Diagnostic co. combines RNA sequencing, ML & 'field of injury' tech. 23% test vol growth, 27% rev growth, 21% EBITDA margin. Potential for annuity-like revenue. New genetic tests for prostate/thyroid cancer could reduce surgeries & health costs. Shares rebounded on strong earnings.

Read full article (1 min)